Drug Profile
Research programme: anti-nucleolin antibodies - CharlestonPharma
Alternative Names: CP101 - CharlestonPharma; CP101.2C8; CP201Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Medical University of South Carolina; University of Louisville
- Developer CharlestonPharma
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cell surface receptor antagonists; Nucleolin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer in USA